EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?

Xianmei Wang iD, Jie Deng, Dai Shi, Zhiyan Liu, Likun Wang, Guofeng Wu

Brain and Behavior · 2026

DOI: 10.1002/brb3.71657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Xianmei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Department, the Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Neuroinflammatory Diseases, Status Epilepticus, Inflammation. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the key Advantageous Discipline Construction Project of Guizhou Provincial Health Commission in 2023 in Emergency Department, Key lab of acute brain injury and function repair in Guizhou Medical University, Leading Discipline Program of the Affiliated Hospital of Guizhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 30% of epilepsy patients develop pharmacoresistant epilepsy (PRE), characterized by persistent seizures refractory to antiseizure medications (ASMs). While neuroinflammation is implicated in both epileptogenesis and treatment failure, its precise temporal contribution remains unclear. This study aimed to delineate the distinct roles of acute versus chronic neuroinflammation in seizure susceptibility and the maintenance of drug resistance.

Methods

Male Sprague‐Dawley rats received acute inflammatory priming via systemic (intraperitoneal) or intracranial (hippocampal) lipopolysaccharide (LPS) administration prior to lithium‐pilocarpine‐induced status epilepticus (SE). Rats were subsequently classified as PRE or pharmacosensitive epilepsy (PSE) based on their response to two sequentially administered ASMs. Outcomes were assessed using video‐EEG monitoring, hippocampal cytokine profiling (IL‐6 and TNF‐α), histopathological analysis of neuronal damage, and peripheral inflammatory markers.

Results

Acute inflammatory priming significantly lowered the threshold for SE induction ( P < 0.05); however, it did not increase the proportion of PRE ( P > 0.05). In contrast, established PRE was characterized by sustained hippocampal neuroinflammation, with markedly elevated IL‐6 and TNF‐α levels compared to PSE and control groups, alongside severe neuronal loss.

Conclusion

These findings reveal a temporal dissociation in the roles of neuroinflammation: acute inflammation acts as a potent initiator of epileptogenesis, whereas chronic, sustained inflammation coincides with the drug‐resistant phenotype. This study refines the prevailing view of neuroinflammation from a static pathogenic factor to a dynamic, phase‐dependent modulator, supporting the rationale for stage‐targeted strategies in PRE. Notably, putative mechanisms linking inflammation to resistance, such as impaired efferocytosis, warrant future experimental validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyNeuroinflammatory DiseasesStatus EpilepticusInflammationAnimalsMaleRats, Sprague-DawleyRatsHippocampusPilocarpineDisease Models, AnimalLipopolysaccharidesAnticonvulsantsTumor Necrosis Factor-alphaInterleukin-6CytokinesElectroencephalography

Stichwörter der Autor:innen

EpilepsyKeywords: cell deathneuroinflammationseizures

Substanzen

PilocarpineLipopolysaccharidesAnticonvulsantsTumor Necrosis Factor-alphaInterleukin-6Cytokines

Autor:innen und Institutionen

  • Emergency Department, the Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China.
  • School of Nursing, Guizhou Medical University, Guiyang City, Guizhou Province, China.
  • Key Laboratory of Endemic and Ethnic Diseases of the Ministry of Education, Guiyang City, Guizhou Province, China.
  • The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China.

ORCID-Profile: Xianmei Wang

Förderung

  • the key Advantageous Discipline Construction Project of Guizhou Provincial Health Commission in 2023 in Emergency Department
  • Key lab of acute brain injury and function repair in Guizhou Medical University
  • Leading Discipline Program of the Affiliated Hospital of Guizhou Medical University
  • the Natural Science Foundation of China
  • the Research Start-up Fund Project for High-level Talents of Guizhou Medical University
  • the Teaching Research Funding Project of the Affiliated Hospital of Guizhou Medical University (School of Clinical Medicine)
  • the National Natural Science Foundation Cultivation Program of Guizhou Medical University
  • the 2025 Annual Scientific Research Project of Guizhou Provincial Nursing Association

Zitieren

APA

Wang, X., Deng, J., Shi, D., Liu, Z., Wang, L., & Wu, G. (2026). Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?. Brain and Behavior. https://doi.org/10.1002/brb3.71657

Vancouver

Wang X, Deng J, Shi D, Liu Z, Wang L, Wu G. Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?. Brain and Behavior. 2026. doi:10.1002/brb3.71657

BibTeX
@article{Wang2026,
  author = {Wang, Xianmei and Deng, Jie and Shi, Dai and Liu, Zhiyan and Wang, Likun and Wu, Guofeng},
  title = {Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71657}
}
Kostenlos starten →